1. Home
  2. PRLD vs PVL Comparison

PRLD vs PVL Comparison

Compare PRLD & PVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRLD
  • PVL
  • Stock Information
  • Founded
  • PRLD 2016
  • PVL 2011
  • Country
  • PRLD United States
  • PVL United States
  • Employees
  • PRLD N/A
  • PVL N/A
  • Industry
  • PRLD Medicinal Chemicals and Botanical Products
  • PVL Oil & Gas Production
  • Sector
  • PRLD Health Care
  • PVL Energy
  • Exchange
  • PRLD Nasdaq
  • PVL Nasdaq
  • Market Cap
  • PRLD 69.1M
  • PVL 57.8M
  • IPO Year
  • PRLD 2020
  • PVL N/A
  • Fundamental
  • Price
  • PRLD $1.36
  • PVL $1.81
  • Analyst Decision
  • PRLD Strong Buy
  • PVL
  • Analyst Count
  • PRLD 3
  • PVL 0
  • Target Price
  • PRLD $4.00
  • PVL N/A
  • AVG Volume (30 Days)
  • PRLD 3.2M
  • PVL 64.1K
  • Earning Date
  • PRLD 10-31-2025
  • PVL 01-01-0001
  • Dividend Yield
  • PRLD N/A
  • PVL 19.78%
  • EPS Growth
  • PRLD N/A
  • PVL N/A
  • EPS
  • PRLD N/A
  • PVL 0.09
  • Revenue
  • PRLD $7,000,000.00
  • PVL $4,598,992.00
  • Revenue This Year
  • PRLD N/A
  • PVL N/A
  • Revenue Next Year
  • PRLD N/A
  • PVL N/A
  • P/E Ratio
  • PRLD N/A
  • PVL $19.35
  • Revenue Growth
  • PRLD N/A
  • PVL 37.78
  • 52 Week Low
  • PRLD $0.61
  • PVL $1.30
  • 52 Week High
  • PRLD $4.22
  • PVL $2.04
  • Technical
  • Relative Strength Index (RSI)
  • PRLD 47.51
  • PVL 45.45
  • Support Level
  • PRLD $1.43
  • PVL $1.79
  • Resistance Level
  • PRLD $4.19
  • PVL $1.88
  • Average True Range (ATR)
  • PRLD 0.40
  • PVL 0.06
  • MACD
  • PRLD -0.01
  • PVL 0.00
  • Stochastic Oscillator
  • PRLD 6.44
  • PVL 33.33

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

About PVL Permianville Royalty Trust Trust Units

Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.

Share on Social Networks: